←
Jacob Bell13,777 posts
Jacob Bell avatar

Jacob Bell

@realJacobBell

Senior reporter covering neuroscience, M&A and cutting-edge drug technologies for @biopharmadive. Formerly @TheStreet, @educationweek, @mcclatchydc.

◷ Joined December 2011▧ 529 Photos and videos
Jacob Bell avatar
Jacob Bell@realJacobBell·1 Jul 2024

In case you missed it, our latest feature takes a deep dive into a very interesting area of drug research: ion channels. These proteins made $VRTX one of the world's wealthiest biotechs. Now others are getting in on the action. #biotech #science #biopharma biopharmadive.com/news/ion-c…

STAT avatar
⟳ Jacob Bell retweeted
STAT@statnews·Oct 13

Helen Branswell, STAT's infectious disease reporter who earned the respect of experts and public health officials with her accessible, prescient dispatches, has died at age 69. trib.al/3bBswKg

BioPharma Dive avatar
⟳ Jacob Bell retweeted
BioPharma Dive@BioPharmaDive·Sep 11

This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree biopharmadive.com/news/biote… by @realJacobBell

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

In a deep dive published today, we explore what’s fueling this boom and how long it might last. Ft. insights from @Stifel; @gibsondunn; @CooleyLLP; @LeerinkPartners; @gilmartinir; @RaymondJames biopharmadive.com/news/biote…

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

With billions of dollars of business on the line, dealmakers are fervently searching for shells that would be good candidates for reverse mergers. Some say there are early signs demand might outstrip the supply.

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

And business is booming. Roughly two dozen reverse mergers involving biotechs have been announced so far this year, more than double the 10 seen across all of 2025, according to a list compiled by life sciences advisory firm JB Strategy Partners.

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

Long dismissed by many top-tier investors, these companies are now the centerpiece of a niche business on Wall Street, where private drug developers are “reverse merging” into them to access all the perks that come with a stock listing.

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

The more media-friendly term is “vehicle,” but both refer to a public company that gets much of its value simply from being public.

Jacob Bell avatar
Jacob Bell@realJacobBell·Sep 10

In the law firms and investment banks that broker some of the world’s biggest biotechnology deals, a not-so-savory word is being thrown around behind closed doors. Shells.

Jacob Bell avatar
Jacob Bell@realJacobBell·Aug 28

Today, we rolled out the first installment of a series where we use data visualization to recap what’s going on across the biopharma industry. This week we’re looking at upswings in biotech M&A and IPOs, and how those are affecting a major stock index. biopharmadive.com/news/biote…

Ben Fidler avatar
⟳ Jacob Bell retweeted
Ben Fidler@BentheFidler·Aug 27

"Maybe this is what all biotech companies are going to be in the future." Here's @realJacobBell on the debut, and ambitions, of Michael Polansky's new, skin-focused #biotech. biopharmadive.com/news/outer…